accountTwo subsidiaries of pharmaceutical giant Johnson & Johnson have agreed to pay more than $81 million stemming from allegedly illegal promotion of the epilepsy drug Topamax for psychiatric uses, the Justice Department announced Thursday...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Pharmaceutical firms agree to settle on Topamax
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account